Latest 23andMe Inc. Stories
MOUNTAIN VIEW, Calif., Feb. 21, 2012 /PRNewswire/ -- Boxing legend Muhammad Ali, who has Parkinson's disease, has teamed up with 23andMe, a leading personal genetics company, in its Parkinson's Disease Research Initiative to enroll 10,000 individuals with Parkinson's disease (PD) to participate in research. Individuals in this online community are helping to advance research in Parkinson's by completing online surveys and sharing their genetic data with researchers. 23andMe's...
CLEVELAND, Feb. 14, 2012 /PRNewswire/ -- In an effort to study the interactions between genomics and Parkinson's disease, Cleveland Clinic has joined the ongoing efforts of 23andMe, a leading personal genetics company, to recruit Parkinson's patients to participate in research by contributing their DNA to a research database and completing online surveys about their health. Currently, little is known about how genes relate to Parkinson's disease, the effectiveness of treatments, or...
MOUNTAIN VIEW, Calif., Jan. 4, 2012 /PRNewswire/ -- 23andMe, a leader in personal genetics, has released its second annual list of what it thinks are the 10 most interesting and significant genetic findings in 2011, as part of an ongoing journey to understand the role of genetics in personal health and human development. (Logo: http://photos.prnewswire.com/prnh/20110107/NY26598LOGO ) "The genetics revolution is well underway and 2011 had some amazing developments," stated Anne...
MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- 23andMe, Inc., an industry leader in personal genetics, announced today that Dr. Ruben Mesa has joined its Myeloproliferative Neoplasms (MPN) research project advisory board. In just over two months since its launch, this first-of-its-kind program has already enrolled over 330 individuals with these rare blood cancers in...
The Scripps Research Institute, funded by The Michael J. Fox Foundation, Will Further Investigate the SGK1 Gene – A First Step Toward Developing Possible Treatments for Parkinson’s Disease 23andMe, Inc., a leading personal genetics company, has announced the first-time discovery of the potentially protective nature of the gene serum/glucocorticoid regulated kinase 1 (SGK1) which appears to be protective against a high-risk leucine-rich repeat kinase 2 (LRRK2) mutation for Parkinson’s...
MOUNTAIN VIEW, Calif., Oct. 25, 2011 /PRNewswire/ -- 23andMe, Inc., a leading personal genetics company, has announced the first-time discovery of the potentially protective nature of the gene serum/glucocorticoid regulated kinase 1 (SGK1) which appears to be protective against a high-risk leucine-rich repeat kinase 2 (LRRK2) mutation for Parkinson's disease (PD). The LRRK2 gene is recognized as a significant risk factor for Parkinson's disease. Of the approximately 1 in 10,000 people who...
Novel Research Paradigm Further Validated with Over 180 Known Genetic Associations Listed by the National Human Genome Research Institute's Replicated Using Self-Reported Medical Data23andMe, Inc., a leading personal genetics company has replicated over 180 genetic associations from a list of associations curated by the National Human Genome Research Institute's Office of Population Genomics ("GWAS Catalog") demonstrating that self-reported medical data is effective and reliable to...
Leading personal genomics company reviews last year's genetic milestones on the journey to understanding the role of genetics in personal health, human development and ancestry23andMe has released its first annual list of what it felt to be the 10 most interesting and significant genetic findings in 2010, as part of an ongoing journey to understand the role of genetics in personal health and human development."Our understanding of the human genome is accelerating at a phenomenal...
MOUNTAIN VIEW, Calif., Jan. 7, 2011 /PRNewswire/ -- 23andMe, a leading personal genomics company, today announced the addition of approximately $9 million to its Series C Financing to bring the total raised in the round to approximately $31 million. 23andMe first announced its Series C Financing in November 2010. With this closing, MPM Capital joins Johnson & Johnson Development Corporation as new investors and MPM Capital Managing Director Ashley Ledbetter Dombkowski, PhD is joining...
MOUNTAIN VIEW, Calif., Nov. 9, 2010 /PRNewswire/ -- 23andMe, Inc., a leading personal genetics company, announced today the closing of its Series C financing. The company raised a total of more than $22 million of funding from a new investor, Johnson & Johnson Development Corporation, and current investors -- including New Enterprise Associates and Google Ventures. "We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and...
